IM
IM
IM
0.1 Results
Factor | Detalis | Total |
N= | 211 | |
Date of Birth | μ ±DS | -663377530.43 ±296823333.5 |
M (min:max) | -694656000 (-1329696000:106531200) | |
Gender | F | 43 (20.4%) |
M | 168 (79.6%) | |
Age | μ ±DS | 66.86 ±9.07 |
M (min:max) | 68 (45.2:86.1) | |
Date of diagnosis | μ ±DS | 1424273554.29 ±98281695.7 |
M (min:max) | 1439208000 (1080864000:1568678400) | |
Year_of_diagnosis | 2008 | 2 (1.0%) |
2009 | 7 (3.3%) | |
2010 | 16 (7.6%) | |
2011 | 16 (7.6%) | |
2012 | 19 (9.0%) | |
2013 | 11 (5.2%) | |
2014 | 19 (9.0%) | |
2015 | 21 (10.0%) | |
2016 | 27 (12.9%) | |
2017 | 24 (11.4%) | |
2018 | 25 (11.9%) | |
2019 | 23 (11.0%) | |
Datum des Exitus | μ ±DS | 1487885373.13 ±90078609.8 |
M (min:max) | 1518739200 (1291075200:1572220800) | |
Survival | μ ±DS | 23.67 ±22.6 |
M (min:max) | 17 (0:114) | |
Status | 0 | 81 (38.4%) |
1 | 123 (58.3%) | |
2 | 7 (3.3%) | |
MRI_diagnosis | 1 | 70 (33.3%) |
0 | 140 (66.7%) | |
CT_Diagnosis | 1 | 122 (58.1%) |
0 | 88 (41.9%) | |
US_Diagnosis | 1 | 72 (34.3%) |
0 | 138 (65.7%) | |
HCC_Screening_18months_before | 1 | 83 (39.3%) |
0 | 128 (60.7%) | |
US_Screening | 1 | 58 (27.5%) |
0 | 153 (72.5%) | |
MRI_Screening | 1 | 18 (8.5%) |
0 | 193 (91.5%) | |
CT_Screening | 1 | 35 (16.6%) |
0 | 176 (83.4%) | |
ASH | 1 | 79 (37.4%) |
0 | 132 (62.6%) | |
NASH | 1 | 55 (26.1%) |
0 | 156 (73.9%) | |
Cirrhosis | 1 | 174 (82.5%) |
0 | 37 (17.5%) | |
HCV | 1 | 57 (27.0%) |
0 | 154 (73.0%) | |
HBc | 1 | 20 (9.5%) |
0 | 191 (90.5%) | |
Group | NASH | 55 (26.1%) |
ASH | 79 (37.4%) | |
VIRAL | 77 (36.5%) | |
Diabetes | 1 | 72 (34.1%) |
0 | 139 (65.9%) | |
Hipertension | 1 | 95 (47.3%) |
0 | 106 (52.7%) | |
Hiperlipidemia | 1 | 30 (14.9%) |
0 | 171 (85.1%) | |
Smoking | 1 | 94 (46.1%) |
0 | 110 (53.9%) | |
Alcohol_Consume | 1 | 61 (29.9%) |
0 | 143 (70.1%) | |
BMI | μ ±DS | 27.41 ±5.19 |
M (min:max) | 26.46 (16.02:46.02) | |
Encephalopathy (acc. to CP score) | 1 | 193 (95.1%) |
2-3 | 10 (4.9%) | |
Ascites (acc. to CP score) | 1 | 163 (80.7%) |
2 | 26 (12.9%) | |
3 | 13 (6.4%) | |
Bilirubin total (µmol/L) | μ ±DS | 22.30 ±26.4 |
M (min:max) | 16 (3:286) | |
INR | μ ±DS | 1.16 ±0.189 |
M (min:max) | 1.11 (0.8:2.07) | |
Albumin (g/L) | μ ±DS | 32.98 ±5.68 |
M (min:max) | 34 (20:44) | |
CHILD | 1 | 131 (65.8%) |
2 | 57 (28.6%) | |
3 | 11 (5.5%) | |
CHILD_A | 1 | 131 (65.8%) |
0 | 68 (34.2%) | |
CHILD_B | 1 | 57 (28.6%) |
0 | 142 (71.4%) | |
CHILD_C | 1 | 11 (5.5%) |
0 | 188 (94.5%) | |
BCLC | 0 | 14 (6.7%) |
1 | 80 (38.1%) | |
2 | 54 (25.7%) | |
3 | 48 (22.9%) | |
4 | 14 (6.7%) | |
BCLC_0 | 1 | 14 (6.7%) |
0 | 196 (93.3%) | |
BCLC_1 | 1 | 80 (38.1%) |
0 | 130 (61.9%) | |
BCLC_2 | 1 | 54 (25.7%) |
0 | 156 (74.3%) | |
BCLC_3 | 1 | 48 (22.9%) |
0 | 162 (77.1%) | |
BCLC_4 | 1 | 14 (6.7%) |
0 | 196 (93.3%) | |
Resection | 1 | 46 (21.9%) |
0 | 164 (78.1%) | |
Transplant | 1 | 8 (3.8%) |
0 | 201 (96.2%) | |
TACE | 1 | 29 (13.9%) |
0 | 180 (86.1%) | |
TAE | 1 | 14 (6.7%) |
0 | 195 (93.3%) | |
RFA | 1 | 8 (3.8%) |
0 | 200 (96.2%) | |
MWA | 1 | 39 (18.7%) |
0 | 170 (81.3%) | |
SIRT | 1 | 7 (3.3%) |
0 | 202 (96.7%) | |
Sistemic_therapy | 1 | 40 (19.1%) |
0 | 169 (80.9%) | |
Curative_treatment | 1 | 83 (39.7%) |
0 | 126 (60.3%) | |
Loco_regional_therapies | 1 | 46 (22.0%) |
0 | 163 (78.0%) | |
No_treatment | 1 | 33 (15.8%) |
0 | 176 (84.2%) | |
Treatment | Curative | 83 (39.7%) |
Transplant | 8 (3.8%) | |
Loco-regional | 46 (22.0%) | |
Systemic | 39 (18.7%) | |
No treatment | 33 (15.8%) | |
Performance Status | 0 | 119 (58.0%) |
1 | 55 (26.8%) | |
2 | 20 (9.8%) | |
3 | 8 (3.9%) | |
4 | 3 (1.5%) | |
PS_0 | 1 | 119 (58.0%) |
0 | 86 (42.0%) | |
PS_1 | 1 | 55 (26.8%) |
0 | 150 (73.2%) | |
PS_2 | 1 | 20 (9.8%) |
0 | 185 (90.2%) | |
PS_3 | 1 | 8 (3.9%) |
0 | 197 (96.1%) | |
PS_4 | 1 | 3 (1.5%) |
0 | 202 (98.5%) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); | ||
Factor | Detalis | Total | NASH | ASH | VIRAL | Statistics |
Group | 211 | 55 (26.1%) | 79 (37.4%) | 77 (36.5%) | ||
Date of Birth | μ ±DS | -663377530.43 ±296823333.5 | -784282143.40 ±255328228.0 | -666367753.85 ±285964701.8 | -575993557.89 ±307829278.3 | 1-way ANOVA: p<0.001 |
M (min:max) | -694656000 (-1329696000:106531200) | -748396800 (-1329696000:-216518400) | -720532800 (-1183334400:106531200) | -505569600 (-1213142400:-7171200) | ||
Gender | F | 43 (20.4%) | 9 (16.4%) | 11 (13.9%) | 23 (29.9%) | V=0.18 (p=0.033) |
M | 168 (79.6%) | 46 (83.6%) | 68 (86.1%) | 54 (70.1%) | ||
Age | μ ±DS | 66.86 ±9.07 | 70.83 ±7.01 | 67.28 ±8.81 | 63.60 ±9.5 | Kruskal-Wallis: p<0.001 |
M (min:max) | 68 (45.2:86.1) | 71.1 (50.9:86.1) | 67.6 (45.2:86) | 61.8 (45.5:83.9) | ||
Date of diagnosis | μ ±DS | 1424273554.29 ±98281695.7 | 1432070574.55 ±100650207.8 | 1436069711.39 ±101326292.2 | 1406369178.95 ±91812854.8 | Kruskal-Wallis: p=0.088 |
M (min:max) | 1439208000 (1080864000:1568678400) | 1451260800 (1219622400:1564099200) | 1460592000 (1201219200:1568678400) | 1416139200 (1080864000:1554940800) | ||
Year_of_diagnosis | 2008 | 2 (1.0%) | 1 (1.8%) | 1 (1.3%) | 0 | V=0.21 (p=0.623) |
2009 | 7 (3.3%) | 2 (3.6%) | 3 (3.8%) | 2 (2.6%) | ||
2010 | 16 (7.6%) | 5 (9.1%) | 6 (7.7%) | 5 (6.5%) | ||
2011 | 16 (7.6%) | 2 (3.6%) | 4 (5.1%) | 10 (13.0%) | ||
2012 | 19 (9.0%) | 6 (10.9%) | 6 (7.7%) | 7 (9.1%) | ||
2013 | 11 (5.2%) | 2 (3.6%) | 5 (6.4%) | 4 (5.2%) | ||
2014 | 19 (9.0%) | 4 (7.3%) | 5 (6.4%) | 10 (13.0%) | ||
2015 | 21 (10.0%) | 6 (10.9%) | 6 (7.7%) | 9 (11.7%) | ||
2016 | 27 (12.9%) | 6 (10.9%) | 10 (12.8%) | 11 (14.3%) | ||
2017 | 24 (11.4%) | 6 (10.9%) | 8 (10.3%) | 10 (13.0%) | ||
2018 | 25 (11.9%) | 7 (12.7%) | 11 (14.1%) | 7 (9.1%) | ||
2019 | 23 (11.0%) | 8 (14.5%) | 13 (16.7%) | 2 (2.6%) | ||
Datum des Exitus | μ ±DS | 1487885373.13 ±90078609.8 | 1489972800.00 ±88551213.9 | 1496952757.89 ±93796883.2 | 1476591819.72 ±87166732.1 | Kruskal-Wallis: p=0.185 |
M (min:max) | 1518739200 (1291075200:1572220800) | 1509883200 (1305417600:1572220800) | 1547078400 (1291075200:1572220800) | 1494979200 (1305849600:1572220800) | ||
Survival | μ ±DS | 23.67 ±22.6 | 21.93 ±23.9 | 23.50 ±23.6 | 25.20 ±20.7 | Kruskal-Wallis: p=0.368 |
M (min:max) | 17 (0:114) | 14 (0:110) | 15 (0:114) | 20.5 (0:93) | ||
Status | 0 | 81 (38.4%) | 23 (41.8%) | 32 (40.5%) | 26 (33.8%) | V=0.08 (p=0.661) |
1 | 123 (58.3%) | 29 (52.7%) | 45 (57.0%) | 49 (63.6%) | ||
2 | 7 (3.3%) | 3 (5.5%) | 2 (2.5%) | 2 (2.6%) | ||
MRI_diagnosis | 1 | 70 (33.3%) | 18 (32.7%) | 24 (30.4%) | 28 (36.8%) | V=0.06 (p=0.691) |
0 | 140 (66.7%) | 37 (67.3%) | 55 (69.6%) | 48 (63.2%) | ||
CT_Diagnosis | 1 | 122 (58.1%) | 33 (60.0%) | 47 (59.5%) | 42 (55.3%) | V=0.04 (p=0.820) |
0 | 88 (41.9%) | 22 (40.0%) | 32 (40.5%) | 34 (44.7%) | ||
US_Diagnosis | 1 | 72 (34.3%) | 20 (36.4%) | 25 (31.6%) | 27 (35.5%) | V=0.04 (p=0.818) |
0 | 138 (65.7%) | 35 (63.6%) | 54 (68.4%) | 49 (64.5%) | ||
HCC_Screening_18months_before | 1 | 83 (39.3%) | 23 (41.8%) | 23 (29.1%) | 37 (48.1%) | V=0.17 (p=0.048) |
0 | 128 (60.7%) | 32 (58.2%) | 56 (70.9%) | 40 (51.9%) | ||
US_Screening | 1 | 58 (27.5%) | 17 (30.9%) | 14 (17.7%) | 27 (35.1%) | V=0.17 (p=0.042) |
0 | 153 (72.5%) | 38 (69.1%) | 65 (82.3%) | 50 (64.9%) | ||
MRI_Screening | 1 | 18 (8.5%) | 6 (10.9%) | 7 (8.9%) | 5 (6.5%) | V=0.06 (p=0.664) |
0 | 193 (91.5%) | 49 (89.1%) | 72 (91.1%) | 72 (93.5%) | ||
CT_Screening | 1 | 35 (16.6%) | 9 (16.4%) | 14 (17.7%) | 12 (15.6%) | V=0.02 (p=0.936) |
0 | 176 (83.4%) | 46 (83.6%) | 65 (82.3%) | 65 (84.4%) | ||
ASH | 1 | 79 (37.4%) | 0 | 79 (100%) | 0 | V=1.00 (p<0.001) |
0 | 132 (62.6%) | 55 (100%) | 0 | 77 (100%) | ||
NASH | 1 | 55 (26.1%) | 55 (100%) | 0 | 0 | V=1.00 (p<0.001) |
0 | 156 (73.9%) | 0 | 79 (100%) | 77 (100%) | ||
Cirrhosis | 1 | 174 (82.5%) | 42 (76.4%) | 70 (88.6%) | 62 (80.5%) | V=0.13 (p=0.159) |
0 | 37 (17.5%) | 13 (23.6%) | 9 (11.4%) | 15 (19.5%) | ||
HCV | 1 | 57 (27.0%) | 0 | 0 | 57 (74.0%) | V=0.80 (p<0.001) |
0 | 154 (73.0%) | 55 (100%) | 79 (100%) | 20 (26.0%) | ||
HBc | 1 | 20 (9.5%) | 0 | 0 | 20 (26.0%) | V=0.43 (p<0.001) |
0 | 191 (90.5%) | 55 (100%) | 79 (100%) | 57 (74.0%) | ||
Diabetes | 1 | 72 (34.1%) | 35 (63.6%) | 18 (22.8%) | 19 (24.7%) | V=0.37 (p<0.001) |
0 | 139 (65.9%) | 20 (36.4%) | 61 (77.2%) | 58 (75.3%) | ||
Hipertension | 1 | 95 (47.3%) | 35 (68.6%) | 35 (46.1%) | 25 (33.8%) | V=0.27 (p<0.001) |
0 | 106 (52.7%) | 16 (31.4%) | 41 (53.9%) | 49 (66.2%) | ||
Hiperlipidemia | 1 | 30 (14.9%) | 16 (31.4%) | 12 (15.8%) | 2 (2.7%) | V=0.31 (p<0.001) |
0 | 171 (85.1%) | 35 (68.6%) | 64 (84.2%) | 72 (97.3%) | ||
Smoking | 1 | 94 (46.1%) | 16 (29.6%) | 48 (60.8%) | 30 (42.3%) | V=0.25 (p=0.001) |
0 | 110 (53.9%) | 38 (70.4%) | 31 (39.2%) | 41 (57.7%) | ||
Alcohol_Consume | 1 | 61 (29.9%) | 7 (13.0%) | 48 (60.8%) | 6 (8.5%) | V=0.54 (p<0.001) |
0 | 143 (70.1%) | 47 (87.0%) | 31 (39.2%) | 65 (91.5%) | ||
BMI | μ ±DS | 27.41 ±5.19 | 30.61 ±4.98 | 26.26 ±4.15 | 26.22 ±5.44 | Kruskal-Wallis: p<0.001 |
M (min:max) | 26.46 (16.02:46.02) | 30.44 (18.48:42.17) | 25.98 (18.63:38.74) | 25.25 (16.02:46.02) | ||
Encephalopathy (acc. to CP score) | 1 | 193 (95.1%) | 51 (96.2%) | 73 (92.4%) | 69 (97.2%) | V=0.10 (p=0.363) |
2-3 | 10 (4.9%) | 2 (3.8%) | 6 (7.6%) | 2 (2.8%) | ||
Ascites (acc. to CP score) | 1 | 163 (80.7%) | 44 (84.6%) | 59 (74.7%) | 60 (84.5%) | V=0.14 (p=0.077) |
2 | 26 (12.9%) | 7 (13.5%) | 10 (12.7%) | 9 (12.7%) | ||
3 | 13 (6.4%) | 1 (1.9%) | 10 (12.7%) | 2 (2.8%) | ||
Bilirubin total (µmol/L) | μ ±DS | 22.30 ±26.4 | 23.88 ±18.2 | 27.42 ±37.6 | 15.69 ±10.7 | Kruskal-Wallis: p=0.010 |
M (min:max) | 16 (3:286) | 18 (5:104) | 16 (3:286) | 12 (4:62) | ||
INR | μ ±DS | 1.16 ±0.189 | 1.16 ±0.162 | 1.19 ±0.222 | 1.12 ±0.163 | Kruskal-Wallis: p=0.076 |
M (min:max) | 1.11 (0.8:2.07) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.08 (0.8:1.9) | ||
Albumin (g/L) | μ ±DS | 32.98 ±5.68 | 33.01 ±4.59 | 31.73 ±6.24 | 34.33 ±5.51 | Kruskal-Wallis: p=0.038 |
M (min:max) | 34 (20:44) | 33 (24:42) | 32.5 (20:42) | 35 (22:44) | ||
CHILD | 1 | 131 (65.8%) | 31 (64.6%) | 44 (55.7%) | 56 (77.8%) | V=0.15 (p=0.060) |
2 | 57 (28.6%) | 15 (31.2%) | 28 (35.4%) | 14 (19.4%) | ||
3 | 11 (5.5%) | 2 (4.2%) | 7 (8.9%) | 2 (2.8%) | ||
CHILD_A | 1 | 131 (65.8%) | 31 (64.6%) | 44 (55.7%) | 56 (77.8%) | V=0.20 (p=0.016) |
0 | 68 (34.2%) | 17 (35.4%) | 35 (44.3%) | 16 (22.2%) | ||
CHILD_B | 1 | 57 (28.6%) | 15 (31.2%) | 28 (35.4%) | 14 (19.4%) | V=0.16 (p=0.085) |
0 | 142 (71.4%) | 33 (68.8%) | 51 (64.6%) | 58 (80.6%) | ||
CHILD_C | 1 | 11 (5.5%) | 2 (4.2%) | 7 (8.9%) | 2 (2.8%) | V=0.12 (p=0.235) |
0 | 188 (94.5%) | 46 (95.8%) | 72 (91.1%) | 70 (97.2%) | ||
BCLC | 0 | 14 (6.7%) | 2 (3.7%) | 9 (11.4%) | 3 (3.9%) | V=0.15 (p=0.272) |
1 | 80 (38.1%) | 21 (38.9%) | 26 (32.9%) | 33 (42.9%) | ||
2 | 54 (25.7%) | 15 (27.8%) | 22 (27.8%) | 17 (22.1%) | ||
3 | 48 (22.9%) | 13 (24.1%) | 14 (17.7%) | 21 (27.3%) | ||
4 | 14 (6.7%) | 3 (5.6%) | 8 (10.1%) | 3 (3.9%) | ||
BCLC_0 | 1 | 14 (6.7%) | 2 (3.7%) | 9 (11.4%) | 3 (3.9%) | V=0.15 (p=0.103) |
0 | 196 (93.3%) | 52 (96.3%) | 70 (88.6%) | 74 (96.1%) | ||
BCLC_1 | 1 | 80 (38.1%) | 21 (38.9%) | 26 (32.9%) | 33 (42.9%) | V=0.09 (p=0.437) |
0 | 130 (61.9%) | 33 (61.1%) | 53 (67.1%) | 44 (57.1%) | ||
BCLC_2 | 1 | 54 (25.7%) | 15 (27.8%) | 22 (27.8%) | 17 (22.1%) | V=0.06 (p=0.656) |
0 | 156 (74.3%) | 39 (72.2%) | 57 (72.2%) | 60 (77.9%) | ||
BCLC_3 | 1 | 48 (22.9%) | 13 (24.1%) | 14 (17.7%) | 21 (27.3%) | V=0.10 (p=0.354) |
0 | 162 (77.1%) | 41 (75.9%) | 65 (82.3%) | 56 (72.7%) | ||
BCLC_4 | 1 | 14 (6.7%) | 3 (5.6%) | 8 (10.1%) | 3 (3.9%) | V=0.11 (p=0.276) |
0 | 196 (93.3%) | 51 (94.4%) | 71 (89.9%) | 74 (96.1%) | ||
Resection | 1 | 46 (21.9%) | 12 (21.8%) | 17 (21.5%) | 17 (22.4%) | V=<0.01 (p=0.992) |
0 | 164 (78.1%) | 43 (78.2%) | 62 (78.5%) | 59 (77.6%) | ||
Transplant | 1 | 8 (3.8%) | 0 | 3 (3.8%) | 5 (6.6%) | V=0.13 (p=0.153) |
0 | 201 (96.2%) | 55 (100%) | 75 (96.2%) | 71 (93.4%) | ||
TACE | 1 | 29 (13.9%) | 7 (12.7%) | 9 (11.5%) | 13 (17.1%) | V=0.07 (p=0.583) |
0 | 180 (86.1%) | 48 (87.3%) | 69 (88.5%) | 63 (82.9%) | ||
TAE | 1 | 14 (6.7%) | 5 (9.1%) | 5 (6.4%) | 4 (5.3%) | V=0.06 (p=0.682) |
0 | 195 (93.3%) | 50 (90.9%) | 73 (93.6%) | 72 (94.7%) | ||
RFA | 1 | 8 (3.8%) | 2 (3.7%) | 1 (1.3%) | 5 (6.6%) | V=0.12 (p=0.232) |
0 | 200 (96.2%) | 52 (96.3%) | 77 (98.7%) | 71 (93.4%) | ||
MWA | 1 | 39 (18.7%) | 11 (20.0%) | 13 (16.7%) | 15 (19.7%) | V=0.04 (p=0.849) |
0 | 170 (81.3%) | 44 (80.0%) | 65 (83.3%) | 61 (80.3%) | ||
SIRT | 1 | 7 (3.3%) | 1 (1.8%) | 2 (2.6%) | 4 (5.3%) | V=0.08 (p=0.495) |
0 | 202 (96.7%) | 54 (98.2%) | 76 (97.4%) | 72 (94.7%) | ||
Sistemic_therapy | 1 | 40 (19.1%) | 12 (21.8%) | 16 (20.5%) | 12 (15.8%) | V=0.07 (p=0.637) |
0 | 169 (80.9%) | 43 (78.2%) | 62 (79.5%) | 64 (84.2%) | ||
Curative_treatment | 1 | 83 (39.7%) | 25 (45.5%) | 27 (34.6%) | 31 (40.8%) | V=0.09 (p=0.440) |
0 | 126 (60.3%) | 30 (54.5%) | 51 (65.4%) | 45 (59.2%) | ||
Loco_regional_therapies | 1 | 46 (22.0%) | 12 (21.8%) | 16 (20.5%) | 18 (23.7%) | V=0.03 (p=0.893) |
0 | 163 (78.0%) | 43 (78.2%) | 62 (79.5%) | 58 (76.3%) | ||
No_treatment | 1 | 33 (15.8%) | 6 (10.9%) | 16 (20.5%) | 11 (14.5%) | V=0.11 (p=0.302) |
0 | 176 (84.2%) | 49 (89.1%) | 62 (79.5%) | 65 (85.5%) | ||
Treatment | Curative | 83 (39.7%) | 25 (45.5%) | 27 (34.6%) | 31 (40.8%) | V=0.14 (p=0.439) |
Transplant | 8 (3.8%) | 0 | 3 (3.8%) | 5 (6.6%) | ||
Loco-regional | 46 (22.0%) | 12 (21.8%) | 16 (20.5%) | 18 (23.7%) | ||
Systemic | 39 (18.7%) | 12 (21.8%) | 16 (20.5%) | 11 (14.5%) | ||
No treatment | 33 (15.8%) | 6 (10.9%) | 16 (20.5%) | 11 (14.5%) | ||
Performance Status | 0 | 119 (58.0%) | 34 (64.2%) | 45 (57.0%) | 40 (54.8%) | V=0.11 (p=0.720) |
1 | 55 (26.8%) | 13 (24.5%) | 20 (25.3%) | 22 (30.1%) | ||
2 | 20 (9.8%) | 4 (7.5%) | 8 (10.1%) | 8 (11.0%) | ||
3 | 8 (3.9%) | 2 (3.8%) | 5 (6.3%) | 1 (1.4%) | ||
4 | 3 (1.5%) | 0 | 1 (1.3%) | 2 (2.7%) | ||
PS_0 | 1 | 119 (58.0%) | 34 (64.2%) | 45 (57.0%) | 40 (54.8%) | V=0.08 (p=0.558) |
0 | 86 (42.0%) | 19 (35.8%) | 34 (43.0%) | 33 (45.2%) | ||
PS_1 | 1 | 55 (26.8%) | 13 (24.5%) | 20 (25.3%) | 22 (30.1%) | V=0.06 (p=0.725) |
0 | 150 (73.2%) | 40 (75.5%) | 59 (74.7%) | 51 (69.9%) | ||
PS_2 | 1 | 20 (9.8%) | 4 (7.5%) | 8 (10.1%) | 8 (11.0%) | V=0.05 (p=0.808) |
0 | 185 (90.2%) | 49 (92.5%) | 71 (89.9%) | 65 (89.0%) | ||
PS_3 | 1 | 8 (3.9%) | 2 (3.8%) | 5 (6.3%) | 1 (1.4%) | V=0.11 (p=0.288) |
0 | 197 (96.1%) | 51 (96.2%) | 74 (93.7%) | 72 (98.6%) | ||
PS_4 | 1 | 3 (1.5%) | 0 | 1 (1.3%) | 2 (2.7%) | V=0.09 (p=0.442) |
0 | 202 (98.5%) | 53 (100%) | 78 (98.7%) | 71 (97.3%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | ||||||
Factor | Detalis | Total | ASH | VIRAL | Statistics |
Group | 156 | 79 (50.6%) | 77 (49.4%) | ||
Date of Birth | μ ±DS | -621767501.30 ±299433537.1 | -666367753.85 ±285964701.8 | -575993557.89 ±307829278.3 | MW: p=0.053 |
M (min:max) | -652536000 (-1213142400:106531200) | -720532800 (-1183334400:106531200) | -505569600 (-1213142400:-7171200) | ||
Gender | F | 34 (21.8%) | 11 (13.9%) | 23 (29.9%) | OR=0.38 [0.17, 0.85] (p=0.020) |
M | 122 (78.2%) | 68 (86.1%) | 54 (70.1%) | ||
Age | μ ±DS | 65.46 ±9.31 | 67.28 ±8.81 | 63.60 ±9.5 | MW: p=0.011 |
M (min:max) | 66.2 (45.2:86) | 67.6 (45.2:86) | 61.8 (45.5:83.9) | ||
Date of diagnosis | μ ±DS | 1421506869.68 ±97608307.9 | 1436069711.39 ±101326292.2 | 1406369178.95 ±91812854.8 | MW: p=0.037 |
M (min:max) | 1434499200 (1080864000:1568678400) | 1460592000 (1201219200:1568678400) | 1416139200 (1080864000:1554940800) | ||
Year_of_diagnosis | 2008 | 1 (0.6%) | 1 (1.3%) | 0 | V=0.32 (p=0.159) |
2009 | 5 (3.2%) | 3 (3.8%) | 2 (2.6%) | ||
2010 | 11 (7.1%) | 6 (7.7%) | 5 (6.5%) | ||
2011 | 14 (9.0%) | 4 (5.1%) | 10 (13.0%) | ||
2012 | 13 (8.4%) | 6 (7.7%) | 7 (9.1%) | ||
2013 | 9 (5.8%) | 5 (6.4%) | 4 (5.2%) | ||
2014 | 15 (9.7%) | 5 (6.4%) | 10 (13.0%) | ||
2015 | 15 (9.7%) | 6 (7.7%) | 9 (11.7%) | ||
2016 | 21 (13.5%) | 10 (12.8%) | 11 (14.3%) | ||
2017 | 18 (11.6%) | 8 (10.3%) | 10 (13.0%) | ||
2018 | 18 (11.6%) | 11 (14.1%) | 7 (9.1%) | ||
2019 | 15 (9.7%) | 13 (16.7%) | 2 (2.6%) | ||
Datum des Exitus | μ ±DS | 1487118563.27 ±90920695.2 | 1496952757.89 ±93796883.2 | 1476591819.72 ±87166732.1 | MW: p=0.061 |
M (min:max) | 1519516800 (1291075200:1572220800) | 1547078400 (1291075200:1572220800) | 1494979200 (1305849600:1572220800) | ||
Survival | μ ±DS | 24.32 ±22.2 | 23.50 ±23.6 | 25.20 ±20.7 | MW: p=0.338 |
M (min:max) | 19 (0:114) | 15 (0:114) | 20.5 (0:93) | ||
Status | 0 | 58 (37.2%) | 32 (40.5%) | 26 (33.8%) | V=0.07 (p=0.682) |
1 | 94 (60.3%) | 45 (57.0%) | 49 (63.6%) | ||
2 | 4 (2.6%) | 2 (2.5%) | 2 (2.6%) | ||
MRI_diagnosis | 1 | 52 (33.5%) | 24 (30.4%) | 28 (36.8%) | OR=0.75 [0.38, 1.46] (p=0.402) |
0 | 103 (66.5%) | 55 (69.6%) | 48 (63.2%) | ||
CT_Diagnosis | 1 | 89 (57.4%) | 47 (59.5%) | 42 (55.3%) | OR=1.19 [0.63, 2.25] (p=0.628) |
0 | 66 (42.6%) | 32 (40.5%) | 34 (44.7%) | ||
US_Diagnosis | 1 | 52 (33.5%) | 25 (31.6%) | 27 (35.5%) | OR=0.84 [0.43, 1.64] (p=0.615) |
0 | 103 (66.5%) | 54 (68.4%) | 49 (64.5%) | ||
HCC_Screening_18months_before | 1 | 60 (38.5%) | 23 (29.1%) | 37 (48.1%) | OR=0.44 [0.23, 0.86] (p=0.021) |
0 | 96 (61.5%) | 56 (70.9%) | 40 (51.9%) | ||
US_Screening | 1 | 41 (26.3%) | 14 (17.7%) | 27 (35.1%) | OR=0.40 [0.19, 0.84] (p=0.018) |
0 | 115 (73.7%) | 65 (82.3%) | 50 (64.9%) | ||
MRI_Screening | 1 | 12 (7.7%) | 7 (8.9%) | 5 (6.5%) | OR=1.40 [0.42, 4.62] (p=0.765) |
0 | 144 (92.3%) | 72 (91.1%) | 72 (93.5%) | ||
CT_Screening | 1 | 26 (16.7%) | 14 (17.7%) | 12 (15.6%) | OR=1.17 [0.50, 2.71] (p=0.831) |
0 | 130 (83.3%) | 65 (82.3%) | 65 (84.4%) | ||
ASH | 1 | 79 (50.6%) | 79 (100%) | 0 | OR=Inf [482.96, Inf] (p<0.001) |
0 | 77 (49.4%) | 0 | 77 (100%) | ||
NASH | 0 | 156 (100%) | 79 (100%) | 77 (100%) | V=NaN (p=1.000) |
Cirrhosis | 1 | 132 (84.6%) | 70 (88.6%) | 62 (80.5%) | OR=1.88 [0.77, 4.60] (p=0.187) |
0 | 24 (15.4%) | 9 (11.4%) | 15 (19.5%) | ||
HCV | 1 | 57 (36.5%) | 0 | 57 (74.0%) | OR=0.00 [0.00, 0.04] (p<0.001) |
0 | 99 (63.5%) | 79 (100%) | 20 (26.0%) | ||
HBc | 1 | 20 (12.8%) | 0 | 20 (26.0%) | OR=0.02 [0.00, 0.30] (p<0.001) |
0 | 136 (87.2%) | 79 (100%) | 57 (74.0%) | ||
Diabetes | 1 | 37 (23.7%) | 18 (22.8%) | 19 (24.7%) | OR=0.90 [0.43, 1.88] (p=0.852) |
0 | 119 (76.3%) | 61 (77.2%) | 58 (75.3%) | ||
Hipertension | 1 | 60 (40.0%) | 35 (46.1%) | 25 (33.8%) | OR=1.67 [0.86, 3.24] (p=0.137) |
0 | 90 (60.0%) | 41 (53.9%) | 49 (66.2%) | ||
Hiperlipidemia | 1 | 14 (9.3%) | 12 (15.8%) | 2 (2.7%) | OR=6.75 [1.46, 31.31] (p=0.009) |
0 | 136 (90.7%) | 64 (84.2%) | 72 (97.3%) | ||
Smoking | 1 | 78 (52.0%) | 48 (60.8%) | 30 (42.3%) | OR=2.12 [1.10, 4.06] (p=0.033) |
0 | 72 (48.0%) | 31 (39.2%) | 41 (57.7%) | ||
Alcohol_Consume | 1 | 54 (36.0%) | 48 (60.8%) | 6 (8.5%) | OR=16.77 [6.48, 43.39] (p<0.001) |
0 | 96 (64.0%) | 31 (39.2%) | 65 (91.5%) | ||
BMI | μ ±DS | 26.24 ±4.77 | 26.26 ±4.15 | 26.22 ±5.44 | MW: p=0.612 |
M (min:max) | 25.73 (16.02:46.02) | 25.98 (18.63:38.74) | 25.25 (16.02:46.02) | ||
Encephalopathy (acc. to CP score) | 1 | 142 (94.7%) | 73 (92.4%) | 69 (97.2%) | OR=0.35 [0.07, 1.81] (p=0.281) |
2-3 | 8 (5.3%) | 6 (7.6%) | 2 (2.8%) | ||
Ascites (acc. to CP score) | 1 | 119 (79.3%) | 59 (74.7%) | 60 (84.5%) | V=0.18 (p=0.083) |
2 | 19 (12.7%) | 10 (12.7%) | 9 (12.7%) | ||
3 | 12 (8.0%) | 10 (12.7%) | 2 (2.8%) | ||
Bilirubin total (µmol/L) | μ ±DS | 21.79 ±28.6 | 27.42 ±37.6 | 15.69 ±10.7 | MW: p=0.017 |
M (min:max) | 14.5 (3:286) | 16 (3:286) | 12 (4:62) | ||
INR | μ ±DS | 1.16 ±0.198 | 1.19 ±0.222 | 1.12 ±0.163 | MW: p=0.038 |
M (min:max) | 1.1 (0.8:2.07) | 1.11 (0.8:2.07) | 1.08 (0.8:1.9) | ||
Albumin (g/L) | μ ±DS | 32.97 ±6.03 | 31.73 ±6.24 | 34.33 ±5.51 | MW: p=0.016 |
M (min:max) | 34 (20:44) | 32.5 (20:42) | 35 (22:44) | ||
CHILD | 1 | 100 (66.2%) | 44 (55.7%) | 56 (77.8%) | V=0.24 (p=0.014) |
2 | 42 (27.8%) | 28 (35.4%) | 14 (19.4%) | ||
3 | 9 (6.0%) | 7 (8.9%) | 2 (2.8%) | ||
CHILD_A | 1 | 100 (66.2%) | 44 (55.7%) | 56 (77.8%) | OR=0.36 [0.18, 0.73] (p=0.006) |
0 | 51 (33.8%) | 35 (44.3%) | 16 (22.2%) | ||
CHILD_B | 1 | 42 (27.8%) | 28 (35.4%) | 14 (19.4%) | OR=2.27 [1.08, 4.79] (p=0.031) |
0 | 109 (72.2%) | 51 (64.6%) | 58 (80.6%) | ||
CHILD_C | 1 | 9 (6.0%) | 7 (8.9%) | 2 (2.8%) | OR=3.40 [0.68, 16.95] (p=0.171) |
0 | 142 (94.0%) | 72 (91.1%) | 70 (97.2%) | ||
BCLC | 0 | 12 (7.7%) | 9 (11.4%) | 3 (3.9%) | V=0.23 (p=0.087) |
1 | 59 (37.8%) | 26 (32.9%) | 33 (42.9%) | ||
2 | 39 (25.0%) | 22 (27.8%) | 17 (22.1%) | ||
3 | 35 (22.4%) | 14 (17.7%) | 21 (27.3%) | ||
4 | 11 (7.1%) | 8 (10.1%) | 3 (3.9%) | ||
BCLC_0 | 1 | 12 (7.7%) | 9 (11.4%) | 3 (3.9%) | OR=3.17 [0.82, 12.20] (p=0.131) |
0 | 144 (92.3%) | 70 (88.6%) | 74 (96.1%) | ||
BCLC_1 | 1 | 59 (37.8%) | 26 (32.9%) | 33 (42.9%) | OR=0.65 [0.34, 1.25] (p=0.248) |
0 | 97 (62.2%) | 53 (67.1%) | 44 (57.1%) | ||
BCLC_2 | 1 | 39 (25.0%) | 22 (27.8%) | 17 (22.1%) | OR=1.36 [0.66, 2.82] (p=0.462) |
0 | 117 (75.0%) | 57 (72.2%) | 60 (77.9%) | ||
BCLC_3 | 1 | 35 (22.4%) | 14 (17.7%) | 21 (27.3%) | OR=0.57 [0.27, 1.23] (p=0.181) |
0 | 121 (77.6%) | 65 (82.3%) | 56 (72.7%) | ||
BCLC_4 | 1 | 11 (7.1%) | 8 (10.1%) | 3 (3.9%) | OR=2.78 [0.71, 10.90] (p=0.210) |
0 | 145 (92.9%) | 71 (89.9%) | 74 (96.1%) | ||
Resection | 1 | 34 (21.9%) | 17 (21.5%) | 17 (22.4%) | OR=0.95 [0.44, 2.04] (p=1.000) |
0 | 121 (78.1%) | 62 (78.5%) | 59 (77.6%) | ||
Transplant | 1 | 8 (5.2%) | 3 (3.8%) | 5 (6.6%) | OR=0.57 [0.13, 2.46] (p=0.492) |
0 | 146 (94.8%) | 75 (96.2%) | 71 (93.4%) | ||
TACE | 1 | 22 (14.3%) | 9 (11.5%) | 13 (17.1%) | OR=0.63 [0.25, 1.58] (p=0.364) |
0 | 132 (85.7%) | 69 (88.5%) | 63 (82.9%) | ||
TAE | 1 | 9 (5.8%) | 5 (6.4%) | 4 (5.3%) | OR=1.23 [0.32, 4.78] (p=1.000) |
0 | 145 (94.2%) | 73 (93.6%) | 72 (94.7%) | ||
RFA | 1 | 6 (3.9%) | 1 (1.3%) | 5 (6.6%) | OR=0.18 [0.02, 1.62] (p=0.114) |
0 | 148 (96.1%) | 77 (98.7%) | 71 (93.4%) | ||
MWA | 1 | 28 (18.2%) | 13 (16.7%) | 15 (19.7%) | OR=0.81 [0.36, 1.85] (p=0.679) |
0 | 126 (81.8%) | 65 (83.3%) | 61 (80.3%) | ||
SIRT | 1 | 6 (3.9%) | 2 (2.6%) | 4 (5.3%) | OR=0.47 [0.08, 2.67] (p=0.439) |
0 | 148 (96.1%) | 76 (97.4%) | 72 (94.7%) | ||
Sistemic_therapy | 1 | 28 (18.2%) | 16 (20.5%) | 12 (15.8%) | OR=1.38 [0.60, 3.14] (p=0.533) |
0 | 126 (81.8%) | 62 (79.5%) | 64 (84.2%) | ||
Curative_treatment | 1 | 58 (37.7%) | 27 (34.6%) | 31 (40.8%) | OR=0.77 [0.40, 1.48] (p=0.506) |
0 | 96 (62.3%) | 51 (65.4%) | 45 (59.2%) | ||
Loco_regional_therapies | 1 | 34 (22.1%) | 16 (20.5%) | 18 (23.7%) | OR=0.83 [0.39, 1.78] (p=0.700) |
0 | 120 (77.9%) | 62 (79.5%) | 58 (76.3%) | ||
No_treatment | 1 | 27 (17.5%) | 16 (20.5%) | 11 (14.5%) | OR=1.52 [0.66, 3.54] (p=0.398) |
0 | 127 (82.5%) | 62 (79.5%) | 65 (85.5%) | ||
Treatment | Curative | 58 (37.7%) | 27 (34.6%) | 31 (40.8%) | V=0.13 (p=0.606) |
Transplant | 8 (5.2%) | 3 (3.8%) | 5 (6.6%) | ||
Loco-regional | 34 (22.1%) | 16 (20.5%) | 18 (23.7%) | ||
Systemic | 27 (17.5%) | 16 (20.5%) | 11 (14.5%) | ||
No treatment | 27 (17.5%) | 16 (20.5%) | 11 (14.5%) | ||
Performance Status | 0 | 85 (55.9%) | 45 (57.0%) | 40 (54.8%) | V=0.14 (p=0.532) |
1 | 42 (27.6%) | 20 (25.3%) | 22 (30.1%) | ||
2 | 16 (10.5%) | 8 (10.1%) | 8 (11.0%) | ||
3 | 6 (3.9%) | 5 (6.3%) | 1 (1.4%) | ||
4 | 3 (2.0%) | 1 (1.3%) | 2 (2.7%) | ||
PS_0 | 1 | 85 (55.9%) | 45 (57.0%) | 40 (54.8%) | OR=1.09 [0.58, 2.07] (p=0.870) |
0 | 67 (44.1%) | 34 (43.0%) | 33 (45.2%) | ||
PS_1 | 1 | 42 (27.6%) | 20 (25.3%) | 22 (30.1%) | OR=0.79 [0.39, 1.60] (p=0.587) |
0 | 110 (72.4%) | 59 (74.7%) | 51 (69.9%) | ||
PS_2 | 1 | 16 (10.5%) | 8 (10.1%) | 8 (11.0%) | OR=0.92 [0.32, 2.58] (p=1.000) |
0 | 136 (89.5%) | 71 (89.9%) | 65 (89.0%) | ||
PS_3 | 1 | 6 (3.9%) | 5 (6.3%) | 1 (1.4%) | OR=4.86 [0.55, 42.67] (p=0.212) |
0 | 146 (96.1%) | 74 (93.7%) | 72 (98.6%) | ||
PS_4 | 1 | 3 (2.0%) | 1 (1.3%) | 2 (2.7%) | OR=0.46 [0.04, 5.13] (p=0.608) |
0 | 149 (98.0%) | 78 (98.7%) | 71 (97.3%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | Total | NASH | VIRAL | Statistics |
Group | 132 | 55 (41.7%) | 77 (58.3%) | ||
Date of Birth | μ ±DS | -661569488.37 ±304286900.1 | -784282143.40 ±255328228.0 | -575993557.89 ±307829278.3 | T-test: p<0.001 |
M (min:max) | -682732800 (-1329696000:-7171200) | -748396800 (-1329696000:-216518400) | -505569600 (-1213142400:-7171200) | ||
Gender | F | 32 (24.2%) | 9 (16.4%) | 23 (29.9%) | OR=0.46 [0.19, 1.09] (p=0.099) |
M | 100 (75.8%) | 46 (83.6%) | 54 (70.1%) | ||
Age | μ ±DS | 66.61 ±9.25 | 70.83 ±7.01 | 63.60 ±9.5 | MW: p<0.001 |
M (min:max) | 68.15 (45.5:86.1) | 71.1 (50.9:86.1) | 61.8 (45.5:83.9) | ||
Date of diagnosis | μ ±DS | 1417159841.22 ±96090604.8 | 1432070574.55 ±100650207.8 | 1406369178.95 ±91812854.8 | MW: p=0.110 |
M (min:max) | 1427760000 (1080864000:1564099200) | 1451260800 (1219622400:1564099200) | 1416139200 (1080864000:1554940800) | ||
Year_of_diagnosis | 2008 | 1 (0.8%) | 1 (1.8%) | 0 | V=0.31 (p=0.292) |
2009 | 4 (3.0%) | 2 (3.6%) | 2 (2.6%) | ||
2010 | 10 (7.6%) | 5 (9.1%) | 5 (6.5%) | ||
2011 | 12 (9.1%) | 2 (3.6%) | 10 (13.0%) | ||
2012 | 13 (9.8%) | 6 (10.9%) | 7 (9.1%) | ||
2013 | 6 (4.5%) | 2 (3.6%) | 4 (5.2%) | ||
2014 | 14 (10.6%) | 4 (7.3%) | 10 (13.0%) | ||
2015 | 15 (11.4%) | 6 (10.9%) | 9 (11.7%) | ||
2016 | 17 (12.9%) | 6 (10.9%) | 11 (14.3%) | ||
2017 | 16 (12.1%) | 6 (10.9%) | 10 (13.0%) | ||
2018 | 14 (10.6%) | 7 (12.7%) | 7 (9.1%) | ||
2019 | 10 (7.6%) | 8 (14.5%) | 2 (2.6%) | ||
Datum des Exitus | μ ±DS | 1482372403.20 ±87664334.7 | 1489972800.00 ±88551213.9 | 1476591819.72 ±87166732.1 | MW: p=0.273 |
M (min:max) | 1496966400 (1305417600:1572220800) | 1509883200 (1305417600:1572220800) | 1494979200 (1305849600:1572220800) | ||
Survival | μ ±DS | 23.77 ±22.1 | 21.93 ±23.9 | 25.20 ±20.7 | MW: p=0.140 |
M (min:max) | 17.5 (0:110) | 14 (0:110) | 20.5 (0:93) | ||
Status | 0 | 49 (37.1%) | 23 (41.8%) | 26 (33.8%) | V=0.12 (p=0.387) |
1 | 78 (59.1%) | 29 (52.7%) | 49 (63.6%) | ||
2 | 5 (3.8%) | 3 (5.5%) | 2 (2.6%) | ||
MRI_diagnosis | 1 | 46 (35.1%) | 18 (32.7%) | 28 (36.8%) | OR=0.83 [0.40, 1.73] (p=0.712) |
0 | 85 (64.9%) | 37 (67.3%) | 48 (63.2%) | ||
CT_Diagnosis | 1 | 75 (57.3%) | 33 (60.0%) | 42 (55.3%) | OR=1.21 [0.60, 2.45] (p=0.597) |
0 | 56 (42.7%) | 22 (40.0%) | 34 (44.7%) | ||
US_Diagnosis | 1 | 47 (35.9%) | 20 (36.4%) | 27 (35.5%) | OR=1.04 [0.50, 2.14] (p=1.000) |
0 | 84 (64.1%) | 35 (63.6%) | 49 (64.5%) | ||
HCC_Screening_18months_before | 1 | 60 (45.5%) | 23 (41.8%) | 37 (48.1%) | OR=0.78 [0.39, 1.56] (p=0.595) |
0 | 72 (54.5%) | 32 (58.2%) | 40 (51.9%) | ||
US_Screening | 1 | 44 (33.3%) | 17 (30.9%) | 27 (35.1%) | OR=0.83 [0.40, 1.73] (p=0.709) |
0 | 88 (66.7%) | 38 (69.1%) | 50 (64.9%) | ||
MRI_Screening | 1 | 11 (8.3%) | 6 (10.9%) | 5 (6.5%) | OR=1.76 [0.51, 6.10] (p=0.525) |
0 | 121 (91.7%) | 49 (89.1%) | 72 (93.5%) | ||
CT_Screening | 1 | 21 (15.9%) | 9 (16.4%) | 12 (15.6%) | OR=1.06 [0.41, 2.72] (p=1.000) |
0 | 111 (84.1%) | 46 (83.6%) | 65 (84.4%) | ||
ASH | 0 | 132 (100%) | 55 (100%) | 77 (100%) | V=NaN (p=1.000) |
NASH | 1 | 55 (41.7%) | 55 (100%) | 0 | OR=Inf [336.27, Inf] (p<0.001) |
0 | 77 (58.3%) | 0 | 77 (100%) | ||
Cirrhosis | 1 | 104 (78.8%) | 42 (76.4%) | 62 (80.5%) | OR=0.78 [0.34, 1.81] (p=0.667) |
0 | 28 (21.2%) | 13 (23.6%) | 15 (19.5%) | ||
HCV | 1 | 57 (43.2%) | 0 | 57 (74.0%) | OR=0.00 [0.00, 0.05] (p<0.001) |
0 | 75 (56.8%) | 55 (100%) | 20 (26.0%) | ||
HBc | 1 | 20 (15.2%) | 0 | 20 (26.0%) | OR=0.03 [0.00, 0.43] (p<0.001) |
0 | 112 (84.8%) | 55 (100%) | 57 (74.0%) | ||
Diabetes | 1 | 54 (40.9%) | 35 (63.6%) | 19 (24.7%) | OR=5.34 [2.51, 11.37] (p<0.001) |
0 | 78 (59.1%) | 20 (36.4%) | 58 (75.3%) | ||
Hipertension | 1 | 60 (48.0%) | 35 (68.6%) | 25 (33.8%) | OR=4.29 [2.00, 9.19] (p<0.001) |
0 | 65 (52.0%) | 16 (31.4%) | 49 (66.2%) | ||
Hiperlipidemia | 1 | 18 (14.4%) | 16 (31.4%) | 2 (2.7%) | OR=16.46 [3.58, 75.58] (p<0.001) |
0 | 107 (85.6%) | 35 (68.6%) | 72 (97.3%) | ||
Smoking | 1 | 46 (36.8%) | 16 (29.6%) | 30 (42.3%) | OR=0.58 [0.27, 1.22] (p=0.190) |
0 | 79 (63.2%) | 38 (70.4%) | 41 (57.7%) | ||
Alcohol_Consume | 1 | 13 (10.4%) | 7 (13.0%) | 6 (8.5%) | OR=1.61 [0.51, 5.11] (p=0.556) |
0 | 112 (89.6%) | 47 (87.0%) | 65 (91.5%) | ||
BMI | μ ±DS | 28.17 ±5.66 | 30.61 ±4.98 | 26.22 ±5.44 | T-test: p<0.001 |
M (min:max) | 26.93 (16.02:46.02) | 30.44 (18.48:42.17) | 25.25 (16.02:46.02) | ||
Encephalopathy (acc. to CP score) | 1 | 120 (96.8%) | 51 (96.2%) | 69 (97.2%) | OR=0.74 [0.10, 5.42] (p=1.000) |
2-3 | 4 (3.2%) | 2 (3.8%) | 2 (2.8%) | ||
Ascites (acc. to CP score) | 1 | 104 (84.6%) | 44 (84.6%) | 60 (84.5%) | V=0.03 (p=0.945) |
2 | 16 (13.0%) | 7 (13.5%) | 9 (12.7%) | ||
3 | 3 (2.4%) | 1 (1.9%) | 2 (2.8%) | ||
Bilirubin total (µmol/L) | μ ±DS | 18.99 ±14.7 | 23.88 ±18.2 | 15.69 ±10.7 | MW: p=0.005 |
M (min:max) | 15 (4:104) | 18 (5:104) | 12 (4:62) | ||
INR | μ ±DS | 1.14 ±0.163 | 1.16 ±0.162 | 1.12 ±0.163 | MW: p=0.082 |
M (min:max) | 1.11 (0.8:1.9) | 1.14 (0.99:1.78) | 1.08 (0.8:1.9) | ||
Albumin (g/L) | μ ±DS | 33.77 ±5.16 | 33.01 ±4.59 | 34.33 ±5.51 | MW: p=0.103 |
M (min:max) | 34 (22:44) | 33 (24:42) | 35 (22:44) | ||
CHILD | 1 | 87 (72.5%) | 31 (64.6%) | 56 (77.8%) | V=0.14 (p=0.284) |
2 | 29 (24.2%) | 15 (31.2%) | 14 (19.4%) | ||
3 | 4 (3.3%) | 2 (4.2%) | 2 (2.8%) | ||
CHILD_A | 1 | 87 (72.5%) | 31 (64.6%) | 56 (77.8%) | OR=0.52 [0.23, 1.17] (p=0.145) |
0 | 33 (27.5%) | 17 (35.4%) | 16 (22.2%) | ||
CHILD_B | 1 | 29 (24.2%) | 15 (31.2%) | 14 (19.4%) | OR=1.88 [0.81, 4.38] (p=0.191) |
0 | 91 (75.8%) | 33 (68.8%) | 58 (80.6%) | ||
CHILD_C | 1 | 4 (3.3%) | 2 (4.2%) | 2 (2.8%) | OR=1.52 [0.21, 11.19] (p=1.000) |
0 | 116 (96.7%) | 46 (95.8%) | 70 (97.2%) | ||
BCLC | 0 | 5 (3.8%) | 2 (3.7%) | 3 (3.9%) | V=0.08 (p=0.930) |
1 | 54 (41.2%) | 21 (38.9%) | 33 (42.9%) | ||
2 | 32 (24.4%) | 15 (27.8%) | 17 (22.1%) | ||
3 | 34 (26.0%) | 13 (24.1%) | 21 (27.3%) | ||
4 | 6 (4.6%) | 3 (5.6%) | 3 (3.9%) | ||
BCLC_0 | 1 | 5 (3.8%) | 2 (3.7%) | 3 (3.9%) | OR=0.95 [0.15, 5.88] (p=1.000) |
0 | 126 (96.2%) | 52 (96.3%) | 74 (96.1%) | ||
BCLC_1 | 1 | 54 (41.2%) | 21 (38.9%) | 33 (42.9%) | OR=0.85 [0.42, 1.72] (p=0.720) |
0 | 77 (58.8%) | 33 (61.1%) | 44 (57.1%) | ||
BCLC_2 | 1 | 32 (24.4%) | 15 (27.8%) | 17 (22.1%) | OR=1.36 [0.61, 3.03] (p=0.537) |
0 | 99 (75.6%) | 39 (72.2%) | 60 (77.9%) | ||
BCLC_3 | 1 | 34 (26.0%) | 13 (24.1%) | 21 (27.3%) | OR=0.85 [0.38, 1.88] (p=0.840) |
0 | 97 (74.0%) | 41 (75.9%) | 56 (72.7%) | ||
BCLC_4 | 1 | 6 (4.6%) | 3 (5.6%) | 3 (3.9%) | OR=1.45 [0.28, 7.48] (p=0.690) |
0 | 125 (95.4%) | 51 (94.4%) | 74 (96.1%) | ||
Resection | 1 | 29 (22.1%) | 12 (21.8%) | 17 (22.4%) | OR=0.97 [0.42, 2.24] (p=1.000) |
0 | 102 (77.9%) | 43 (78.2%) | 59 (77.6%) | ||
Transplant | 1 | 5 (3.8%) | 0 | 5 (6.6%) | OR=0.12 [0.01, 2.16] (p=0.074) |
0 | 126 (96.2%) | 55 (100%) | 71 (93.4%) | ||
TACE | 1 | 20 (15.3%) | 7 (12.7%) | 13 (17.1%) | OR=0.71 [0.26, 1.91] (p=0.624) |
0 | 111 (84.7%) | 48 (87.3%) | 63 (82.9%) | ||
TAE | 1 | 9 (6.9%) | 5 (9.1%) | 4 (5.3%) | OR=1.80 [0.46, 7.04] (p=0.491) |
0 | 122 (93.1%) | 50 (90.9%) | 72 (94.7%) | ||
RFA | 1 | 7 (5.4%) | 2 (3.7%) | 5 (6.6%) | OR=0.55 [0.10, 2.93] (p=0.699) |
0 | 123 (94.6%) | 52 (96.3%) | 71 (93.4%) | ||
MWA | 1 | 26 (19.8%) | 11 (20.0%) | 15 (19.7%) | OR=1.02 [0.43, 2.42] (p=1.000) |
0 | 105 (80.2%) | 44 (80.0%) | 61 (80.3%) | ||
SIRT | 1 | 5 (3.8%) | 1 (1.8%) | 4 (5.3%) | OR=0.33 [0.04, 3.07] (p=0.398) |
0 | 126 (96.2%) | 54 (98.2%) | 72 (94.7%) | ||
Sistemic_therapy | 1 | 24 (18.3%) | 12 (21.8%) | 12 (15.8%) | OR=1.49 [0.61, 3.62] (p=0.493) |
0 | 107 (81.7%) | 43 (78.2%) | 64 (84.2%) | ||
Curative_treatment | 1 | 56 (42.7%) | 25 (45.5%) | 31 (40.8%) | OR=1.21 [0.60, 2.44] (p=0.721) |
0 | 75 (57.3%) | 30 (54.5%) | 45 (59.2%) | ||
Loco_regional_therapies | 1 | 30 (22.9%) | 12 (21.8%) | 18 (23.7%) | OR=0.90 [0.39, 2.06] (p=0.836) |
0 | 101 (77.1%) | 43 (78.2%) | 58 (76.3%) | ||
No_treatment | 1 | 17 (13.0%) | 6 (10.9%) | 11 (14.5%) | OR=0.72 [0.25, 2.09] (p=0.608) |
0 | 114 (87.0%) | 49 (89.1%) | 65 (85.5%) | ||
Treatment | Curative | 56 (42.7%) | 25 (45.5%) | 31 (40.8%) | V=0.20 (p=0.275) |
Transplant | 5 (3.8%) | 0 | 5 (6.6%) | ||
Loco-regional | 30 (22.9%) | 12 (21.8%) | 18 (23.7%) | ||
Systemic | 23 (17.6%) | 12 (21.8%) | 11 (14.5%) | ||
No treatment | 17 (13.0%) | 6 (10.9%) | 11 (14.5%) | ||
Performance Status | 0 | 74 (58.7%) | 34 (64.2%) | 40 (54.8%) | V=0.16 (p=0.497) |
1 | 35 (27.8%) | 13 (24.5%) | 22 (30.1%) | ||
2 | 12 (9.5%) | 4 (7.5%) | 8 (11.0%) | ||
3 | 3 (2.4%) | 2 (3.8%) | 1 (1.4%) | ||
4 | 2 (1.6%) | 0 | 2 (2.7%) | ||
PS_0 | 1 | 74 (58.7%) | 34 (64.2%) | 40 (54.8%) | OR=1.48 [0.71, 3.05] (p=0.360) |
0 | 52 (41.3%) | 19 (35.8%) | 33 (45.2%) | ||
PS_1 | 1 | 35 (27.8%) | 13 (24.5%) | 22 (30.1%) | OR=0.75 [0.34, 1.68] (p=0.549) |
0 | 91 (72.2%) | 40 (75.5%) | 51 (69.9%) | ||
PS_2 | 1 | 12 (9.5%) | 4 (7.5%) | 8 (11.0%) | OR=0.66 [0.19, 2.33] (p=0.760) |
0 | 114 (90.5%) | 49 (92.5%) | 65 (89.0%) | ||
PS_3 | 1 | 3 (2.4%) | 2 (3.8%) | 1 (1.4%) | OR=2.82 [0.25, 31.98] (p=0.572) |
0 | 123 (97.6%) | 51 (96.2%) | 72 (98.6%) | ||
PS_4 | 1 | 2 (1.6%) | 0 | 2 (2.7%) | OR=0.27 [0.01, 5.68] (p=0.509) |
0 | 124 (98.4%) | 53 (100%) | 71 (97.3%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | Total | NASH | ASH | Statistics |
Group | 134 | 55 (41.0%) | 79 (59.0%) | ||
Date of Birth | μ ±DS | -714073575.57 ±279085228.9 | -784282143.40 ±255328228.0 | -666367753.85 ±285964701.8 | T-test: p=0.017 |
M (min:max) | -734486400 (-1329696000:106531200) | -748396800 (-1329696000:-216518400) | -720532800 (-1183334400:106531200) | ||
Gender | F | 20 (14.9%) | 9 (16.4%) | 11 (13.9%) | OR=1.21 [0.46, 3.15] (p=0.806) |
M | 114 (85.1%) | 46 (83.6%) | 68 (86.1%) | ||
Age | μ ±DS | 68.74 ±8.28 | 70.83 ±7.01 | 67.28 ±8.81 | MW: p=0.031 |
M (min:max) | 70 (45.2:86.1) | 71.1 (50.9:86.1) | 67.6 (45.2:86) | ||
Date of diagnosis | μ ±DS | 1434428274.63 ±100689018.0 | 1432070574.55 ±100650207.8 | 1436069711.39 ±101326292.2 | MW: p=0.790 |
M (min:max) | 1454284800 (1201219200:1568678400) | 1451260800 (1219622400:1564099200) | 1460592000 (1201219200:1568678400) | ||
Year_of_diagnosis | 2008 | 2 (1.5%) | 1 (1.8%) | 1 (1.3%) | V=0.12 (p=0.999) |
2009 | 5 (3.8%) | 2 (3.6%) | 3 (3.8%) | ||
2010 | 11 (8.3%) | 5 (9.1%) | 6 (7.7%) | ||
2011 | 6 (4.5%) | 2 (3.6%) | 4 (5.1%) | ||
2012 | 12 (9.0%) | 6 (10.9%) | 6 (7.7%) | ||
2013 | 7 (5.3%) | 2 (3.6%) | 5 (6.4%) | ||
2014 | 9 (6.8%) | 4 (7.3%) | 5 (6.4%) | ||
2015 | 12 (9.0%) | 6 (10.9%) | 6 (7.7%) | ||
2016 | 16 (12.0%) | 6 (10.9%) | 10 (12.8%) | ||
2017 | 14 (10.5%) | 6 (10.9%) | 8 (10.3%) | ||
2018 | 18 (13.5%) | 7 (12.7%) | 11 (14.1%) | ||
2019 | 21 (15.8%) | 8 (14.5%) | 13 (16.7%) | ||
Datum des Exitus | μ ±DS | 1494053390.77 ±91370572.7 | 1489972800.00 ±88551213.9 | 1496952757.89 ±93796883.2 | MW: p=0.737 |
M (min:max) | 1539086400 (1291075200:1572220800) | 1509883200 (1305417600:1572220800) | 1547078400 (1291075200:1572220800) | ||
Survival | μ ±DS | 22.85 ±23.6 | 21.93 ±23.9 | 23.50 ±23.6 | MW: p=0.884 |
M (min:max) | 15 (0:114) | 14 (0:110) | 15 (0:114) | ||
Status | 0 | 55 (41.0%) | 23 (41.8%) | 32 (40.5%) | V=0.08 (p=0.650) |
1 | 74 (55.2%) | 29 (52.7%) | 45 (57.0%) | ||
2 | 5 (3.7%) | 3 (5.5%) | 2 (2.5%) | ||
MRI_diagnosis | 1 | 42 (31.3%) | 18 (32.7%) | 24 (30.4%) | OR=1.11 [0.53, 2.34] (p=0.850) |
0 | 92 (68.7%) | 37 (67.3%) | 55 (69.6%) | ||
CT_Diagnosis | 1 | 80 (59.7%) | 33 (60.0%) | 47 (59.5%) | OR=1.02 [0.51, 2.06] (p=1.000) |
0 | 54 (40.3%) | 22 (40.0%) | 32 (40.5%) | ||
US_Diagnosis | 1 | 45 (33.6%) | 20 (36.4%) | 25 (31.6%) | OR=1.23 [0.60, 2.55] (p=0.582) |
0 | 89 (66.4%) | 35 (63.6%) | 54 (68.4%) | ||
HCC_Screening_18months_before | 1 | 46 (34.3%) | 23 (41.8%) | 23 (29.1%) | OR=1.75 [0.85, 3.61] (p=0.142) |
0 | 88 (65.7%) | 32 (58.2%) | 56 (70.9%) | ||
US_Screening | 1 | 31 (23.1%) | 17 (30.9%) | 14 (17.7%) | OR=2.08 [0.92, 4.68] (p=0.096) |
0 | 103 (76.9%) | 38 (69.1%) | 65 (82.3%) | ||
MRI_Screening | 1 | 13 (9.7%) | 6 (10.9%) | 7 (8.9%) | OR=1.26 [0.40, 3.97] (p=0.770) |
0 | 121 (90.3%) | 49 (89.1%) | 72 (91.1%) | ||
CT_Screening | 1 | 23 (17.2%) | 9 (16.4%) | 14 (17.7%) | OR=0.91 [0.36, 2.28] (p=1.000) |
0 | 111 (82.8%) | 46 (83.6%) | 65 (82.3%) | ||
ASH | 1 | 79 (59.0%) | 0 | 79 (100%) | OR=0.00 [0.00, 0.00] (p<0.001) |
0 | 55 (41.0%) | 55 (100%) | 0 | ||
NASH | 1 | 55 (41.0%) | 55 (100%) | 0 | OR=Inf [345.00, Inf] (p<0.001) |
0 | 79 (59.0%) | 0 | 79 (100%) | ||
Cirrhosis | 1 | 112 (83.6%) | 42 (76.4%) | 70 (88.6%) | OR=0.42 [0.16, 1.05] (p=0.095) |
0 | 22 (16.4%) | 13 (23.6%) | 9 (11.4%) | ||
HCV | 0 | 134 (100%) | 55 (100%) | 79 (100%) | V=NaN (p=1.000) |
HBc | 0 | 134 (100%) | 55 (100%) | 79 (100%) | V=NaN (p=1.000) |
Diabetes | 1 | 53 (39.6%) | 35 (63.6%) | 18 (22.8%) | OR=5.93 [2.77, 12.69] (p<0.001) |
0 | 81 (60.4%) | 20 (36.4%) | 61 (77.2%) | ||
Hipertension | 1 | 70 (55.1%) | 35 (68.6%) | 35 (46.1%) | OR=2.56 [1.22, 5.39] (p=0.018) |
0 | 57 (44.9%) | 16 (31.4%) | 41 (53.9%) | ||
Hiperlipidemia | 1 | 28 (22.0%) | 16 (31.4%) | 12 (15.8%) | OR=2.44 [1.04, 5.73] (p=0.050) |
0 | 99 (78.0%) | 35 (68.6%) | 64 (84.2%) | ||
Smoking | 1 | 64 (48.1%) | 16 (29.6%) | 48 (60.8%) | OR=0.27 [0.13, 0.57] (p<0.001) |
0 | 69 (51.9%) | 38 (70.4%) | 31 (39.2%) | ||
Alcohol_Consume | 1 | 55 (41.4%) | 7 (13.0%) | 48 (60.8%) | OR=0.10 [0.04, 0.24] (p<0.001) |
0 | 78 (58.6%) | 47 (87.0%) | 31 (39.2%) | ||
BMI | μ ±DS | 28.02 ±4.97 | 30.61 ±4.98 | 26.26 ±4.15 | MW: p<0.001 |
M (min:max) | 27.34 (18.48:42.17) | 30.44 (18.48:42.17) | 25.98 (18.63:38.74) | ||
Encephalopathy (acc. to CP score) | 1 | 124 (93.9%) | 51 (96.2%) | 73 (92.4%) | OR=2.10 [0.41, 10.80] (p=0.474) |
2-3 | 8 (6.1%) | 2 (3.8%) | 6 (7.6%) | ||
Ascites (acc. to CP score) | 1 | 103 (78.6%) | 44 (84.6%) | 59 (74.7%) | V=0.19 (p=0.095) |
2 | 17 (13.0%) | 7 (13.5%) | 10 (12.7%) | ||
3 | 11 (8.4%) | 1 (1.9%) | 10 (12.7%) | ||
Bilirubin total (µmol/L) | μ ±DS | 26.06 ±31.6 | 23.88 ±18.2 | 27.42 ±37.6 | MW: p=0.571 |
M (min:max) | 17 (3:286) | 18 (5:104) | 16 (3:286) | ||
INR | μ ±DS | 1.18 ±0.2 | 1.16 ±0.162 | 1.19 ±0.222 | MW: p=0.686 |
M (min:max) | 1.13 (0.8:2.07) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 32.25 ±5.65 | 33.01 ±4.59 | 31.73 ±6.24 | MW: p=0.334 |
M (min:max) | 33 (20:42) | 33 (24:42) | 32.5 (20:42) | ||
CHILD | 1 | 75 (59.1%) | 31 (64.6%) | 44 (55.7%) | V=0.11 (p=0.476) |
2 | 43 (33.9%) | 15 (31.2%) | 28 (35.4%) | ||
3 | 9 (7.1%) | 2 (4.2%) | 7 (8.9%) | ||
CHILD_A | 1 | 75 (59.1%) | 31 (64.6%) | 44 (55.7%) | OR=1.45 [0.69, 3.04] (p=0.357) |
0 | 52 (40.9%) | 17 (35.4%) | 35 (44.3%) | ||
CHILD_B | 1 | 43 (33.9%) | 15 (31.2%) | 28 (35.4%) | OR=0.83 [0.39, 1.78] (p=0.701) |
0 | 84 (66.1%) | 33 (68.8%) | 51 (64.6%) | ||
CHILD_C | 1 | 9 (7.1%) | 2 (4.2%) | 7 (8.9%) | OR=0.45 [0.09, 2.25] (p=0.481) |
0 | 118 (92.9%) | 46 (95.8%) | 72 (91.1%) | ||
BCLC | 0 | 11 (8.3%) | 2 (3.7%) | 9 (11.4%) | V=0.17 (p=0.397) |
1 | 47 (35.3%) | 21 (38.9%) | 26 (32.9%) | ||
2 | 37 (27.8%) | 15 (27.8%) | 22 (27.8%) | ||
3 | 27 (20.3%) | 13 (24.1%) | 14 (17.7%) | ||
4 | 11 (8.3%) | 3 (5.6%) | 8 (10.1%) | ||
BCLC_0 | 1 | 11 (8.3%) | 2 (3.7%) | 9 (11.4%) | OR=0.30 [0.06, 1.44] (p=0.198) |
0 | 122 (91.7%) | 52 (96.3%) | 70 (88.6%) | ||
BCLC_1 | 1 | 47 (35.3%) | 21 (38.9%) | 26 (32.9%) | OR=1.30 [0.63, 2.67] (p=0.580) |
0 | 86 (64.7%) | 33 (61.1%) | 53 (67.1%) | ||
BCLC_2 | 1 | 37 (27.8%) | 15 (27.8%) | 22 (27.8%) | OR=1.00 [0.46, 2.16] (p=1.000) |
0 | 96 (72.2%) | 39 (72.2%) | 57 (72.2%) | ||
BCLC_3 | 1 | 27 (20.3%) | 13 (24.1%) | 14 (17.7%) | OR=1.47 [0.63, 3.44] (p=0.388) |
0 | 106 (79.7%) | 41 (75.9%) | 65 (82.3%) | ||
BCLC_4 | 1 | 11 (8.3%) | 3 (5.6%) | 8 (10.1%) | OR=0.52 [0.13, 2.06] (p=0.524) |
0 | 122 (91.7%) | 51 (94.4%) | 71 (89.9%) | ||
Resection | 1 | 29 (21.6%) | 12 (21.8%) | 17 (21.5%) | OR=1.02 [0.44, 2.35] (p=1.000) |
0 | 105 (78.4%) | 43 (78.2%) | 62 (78.5%) | ||
Transplant | 1 | 3 (2.3%) | 0 | 3 (3.8%) | OR=0.19 [0.01, 3.84] (p=0.267) |
0 | 130 (97.7%) | 55 (100%) | 75 (96.2%) | ||
TACE | 1 | 16 (12.0%) | 7 (12.7%) | 9 (11.5%) | OR=1.12 [0.39, 3.21] (p=1.000) |
0 | 117 (88.0%) | 48 (87.3%) | 69 (88.5%) | ||
TAE | 1 | 10 (7.5%) | 5 (9.1%) | 5 (6.4%) | OR=1.46 [0.40, 5.31] (p=0.740) |
0 | 123 (92.5%) | 50 (90.9%) | 73 (93.6%) | ||
RFA | 1 | 3 (2.3%) | 2 (3.7%) | 1 (1.3%) | OR=2.96 [0.26, 33.51] (p=0.567) |
0 | 129 (97.7%) | 52 (96.3%) | 77 (98.7%) | ||
MWA | 1 | 24 (18.0%) | 11 (20.0%) | 13 (16.7%) | OR=1.25 [0.51, 3.04] (p=0.652) |
0 | 109 (82.0%) | 44 (80.0%) | 65 (83.3%) | ||
SIRT | 1 | 3 (2.3%) | 1 (1.8%) | 2 (2.6%) | OR=0.70 [0.06, 7.96] (p=1.000) |
0 | 130 (97.7%) | 54 (98.2%) | 76 (97.4%) | ||
Sistemic_therapy | 1 | 28 (21.1%) | 12 (21.8%) | 16 (20.5%) | OR=1.08 [0.47, 2.51] (p=1.000) |
0 | 105 (78.9%) | 43 (78.2%) | 62 (79.5%) | ||
Curative_treatment | 1 | 52 (39.1%) | 25 (45.5%) | 27 (34.6%) | OR=1.57 [0.78, 3.19] (p=0.214) |
0 | 81 (60.9%) | 30 (54.5%) | 51 (65.4%) | ||
Loco_regional_therapies | 1 | 28 (21.1%) | 12 (21.8%) | 16 (20.5%) | OR=1.08 [0.47, 2.51] (p=1.000) |
0 | 105 (78.9%) | 43 (78.2%) | 62 (79.5%) | ||
No_treatment | 1 | 22 (16.5%) | 6 (10.9%) | 16 (20.5%) | OR=0.47 [0.17, 1.30] (p=0.162) |
0 | 111 (83.5%) | 49 (89.1%) | 62 (79.5%) | ||
Treatment | Curative | 52 (39.1%) | 25 (45.5%) | 27 (34.6%) | V=0.19 (p=0.294) |
Transplant | 3 (2.3%) | 0 | 3 (3.8%) | ||
Loco-regional | 28 (21.1%) | 12 (21.8%) | 16 (20.5%) | ||
Systemic | 28 (21.1%) | 12 (21.8%) | 16 (20.5%) | ||
No treatment | 22 (16.5%) | 6 (10.9%) | 16 (20.5%) | ||
Performance Status | 0 | 79 (59.8%) | 34 (64.2%) | 45 (57.0%) | V=0.11 (p=0.813) |
1 | 33 (25.0%) | 13 (24.5%) | 20 (25.3%) | ||
2 | 12 (9.1%) | 4 (7.5%) | 8 (10.1%) | ||
3 | 7 (5.3%) | 2 (3.8%) | 5 (6.3%) | ||
4 | 1 (0.8%) | 0 | 1 (1.3%) | ||
PS_0 | 1 | 79 (59.8%) | 34 (64.2%) | 45 (57.0%) | OR=1.35 [0.66, 2.77] (p=0.471) |
0 | 53 (40.2%) | 19 (35.8%) | 34 (43.0%) | ||
PS_1 | 1 | 33 (25.0%) | 13 (24.5%) | 20 (25.3%) | OR=0.96 [0.43, 2.15] (p=1.000) |
0 | 99 (75.0%) | 40 (75.5%) | 59 (74.7%) | ||
PS_2 | 1 | 12 (9.1%) | 4 (7.5%) | 8 (10.1%) | OR=0.72 [0.21, 2.54] (p=0.762) |
0 | 120 (90.9%) | 49 (92.5%) | 71 (89.9%) | ||
PS_3 | 1 | 7 (5.3%) | 2 (3.8%) | 5 (6.3%) | OR=0.58 [0.11, 3.11] (p=0.701) |
0 | 125 (94.7%) | 51 (96.2%) | 74 (93.7%) | ||
PS_4 | 1 | 1 (0.8%) | 0 | 1 (1.3%) | OR=0.49 [0.02, 12.23] (p=1.000) |
0 | 131 (99.2%) | 53 (100%) | 78 (98.7%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
0.2 Cox
| LR Chisq | Df | Pr(>Chisq) | |
|---|---|---|---|
| Treatment | 22.143 | 4 | 0.000 |
| Group | 7.319 | 2 | 0.026 |
| Age | 1.176 | 1 | 0.278 |
| Gender | 0.006 | 1 | 0.938 |
| Diabetes | 0.037 | 1 | 0.847 |
| Hipertension | 2.567 | 1 | 0.109 |
| Hiperlipidemia | 0.000 | 1 | 0.986 |
| Smoking | 6.571 | 1 | 0.010 |
| Alcohol_Consume | 2.234 | 1 | 0.135 |
| BMI | 4.080 | 1 | 0.043 |
| Bilirubin.total..µmol.L. | 10.388 | 1 | 0.001 |
| INR | 7.363 | 1 | 0.007 |
| Albumin..g.L. | 0.888 | 1 | 0.346 |
| BCLC | 6.218 | 4 | 0.183 |
| CHILD | 3.901 | 2 | 0.142 |
| Encephalopathy..according.to.Child.Pugh.score. | 0.027 | 1 | 0.870 |
| Ascites..according.to.Child.Pugh.score. | 3.894 | 2 | 0.143 |
| Performance.Status | 3.794 | 4 | 0.435 |
0.3 Univariate:
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 65 4 0.944 0.0270 0.893 0.999
36 26 20 0.608 0.0633 0.496 0.746
60 10 7 0.388 0.0794 0.260 0.580
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 7 2 0.75 0.153 0.503 1
36 2 2 0.45 0.188 0.198 1
60 2 0 0.45 0.188 0.198 1
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 38 2 0.9540 0.0318 0.8937 1.000
36 10 23 0.3158 0.0781 0.1945 0.513
60 3 7 0.0947 0.0514 0.0327 0.274
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 12 20 0.417 0.0873 0.2766 0.628
36 5 2 0.334 0.0875 0.1994 0.558
60 2 3 0.133 0.0810 0.0406 0.439
Treatment=No treatment
time n.risk n.event survival std.err
12.0000 3.0000 21.0000 0.1698 0.0767
lower 95% CI upper 95% CI
0.0701 0.4114 
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional
Transplant 0.943 - -
Loco-regional 0.007 0.395 -
Systemic 0.000001150703 0.069 0.036
No treatment < 0.0000000000000002 0.001 0.000000000003
Systemic
Transplant -
Loco-regional -
Systemic -
No treatment 0.000818611500
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Group=NASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 29 11 0.772 0.0609 0.6617 0.901
36 10 13 0.388 0.0826 0.2560 0.589
60 4 5 0.175 0.0744 0.0759 0.403
Group=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 45 21 0.698 0.0555 0.597 0.816
36 17 15 0.406 0.0667 0.294 0.561
60 8 7 0.221 0.0635 0.126 0.388
Group=VIRAL
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 51 18 0.741 0.0526 0.644 0.851
36 16 22 0.367 0.0632 0.262 0.514
60 5 5 0.205 0.0664 0.109 0.387
Pairwise comparisons using Log-Rank test
data: db and Group
NASH ASH
ASH 1 -
VIRAL 1 1
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Gender=F
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 28 11 0.713 0.0733 0.583 0.872
36 7 9 0.374 0.0920 0.231 0.606
60 4 1 0.299 0.0994 0.156 0.574
Gender=M
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 97 39 0.740 0.0361 0.672 0.814
36 36 41 0.389 0.0447 0.310 0.487
60 13 16 0.187 0.0416 0.121 0.290
Pairwise comparisons using Log-Rank test
data: db and Gender
F
M 0.5
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Diabetes=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 42 19 0.718 0.0551 0.618 0.835
36 17 12 0.475 0.0686 0.358 0.631
60 6 7 0.224 0.0735 0.118 0.426
Diabetes=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 83 31 0.743 0.0401 0.668 0.826
36 26 38 0.344 0.0486 0.261 0.454
60 11 10 0.195 0.0454 0.124 0.308
Pairwise comparisons using Log-Rank test
data: db and Diabetes
1
0 0.5
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Hipertension=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 56 21 0.757 0.0464 0.671 0.854
36 20 18 0.458 0.0632 0.349 0.600
60 8 7 0.257 0.0675 0.154 0.430
Hipertension=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 67 29 0.706 0.0460 0.621 0.802
36 22 31 0.330 0.0515 0.243 0.448
60 9 9 0.176 0.0470 0.104 0.297
Pairwise comparisons using Log-Rank test
data: db and Hipertension
1
0 0.2
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Hiperlipidemia=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 16 4 0.855 0.0671 0.7331 0.997
36 5 8 0.416 0.1142 0.2427 0.712
60 2 2 0.208 0.1186 0.0679 0.636
Hiperlipidemia=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 107 46 0.710 0.0362 0.642 0.784
36 37 41 0.379 0.0430 0.304 0.474
60 15 14 0.211 0.0417 0.143 0.311
Pairwise comparisons using Log-Rank test
data: db and Hiperlipidemia
1
0 0.9
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Smoking=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 43 29 0.642 0.0542 0.5441 0.757
36 5 16 0.259 0.0718 0.1503 0.446
60 2 2 0.129 0.0740 0.0422 0.397
Smoking=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 77 21 0.792 0.0404 0.717 0.876
36 37 30 0.465 0.0518 0.374 0.578
60 15 15 0.244 0.0499 0.163 0.364
Pairwise comparisons using Log-Rank test
data: db and Smoking
1
0 0.008
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Alcohol_Consume=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 26 19 0.628 0.0690 0.507 0.779
36 6 7 0.374 0.0891 0.235 0.597
60 3 1 0.312 0.0936 0.173 0.562
Alcohol_Consume=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 94 31 0.763 0.0373 0.694 0.840
36 36 39 0.408 0.0467 0.326 0.510
60 14 16 0.195 0.0434 0.126 0.302
Pairwise comparisons using Log-Rank test
data: db and Alcohol_Consume
1
0 0.5
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
BCLC=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 11 1 0.929 0.0688 0.803 1.000
36 5 2 0.696 0.1512 0.455 1.000
60 3 2 0.418 0.1775 0.182 0.961
BCLC=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 60 8 0.885 0.0382 0.814 0.963
36 21 20 0.541 0.0655 0.427 0.686
60 7 5 0.349 0.0817 0.220 0.552
BCLC=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 33 9 0.804 0.0591 0.6957 0.928
36 12 16 0.359 0.0797 0.2325 0.555
60 5 7 0.150 0.0609 0.0673 0.332
BCLC=3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 19 22 0.4997 0.0765 0.3702 0.674
36 5 10 0.2120 0.0681 0.1130 0.398
60 2 3 0.0848 0.0538 0.0244 0.294
BCLC=4
time n.risk n.event survival std.err
12.0000 1.0000 10.0000 0.2308 0.1169
lower 95% CI upper 95% CI
0.0855 0.6226 
Pairwise comparisons using Log-Rank test
data: db and BCLC
0 1 2 3
1 0.434 - - -
2 0.063 0.057 - -
3 0.010 0.0000292668 0.025 -
4 0.0004076731 0.0000000001 0.0000012648 0.006
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
CHILD=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 92 18 0.847 0.0334 0.784 0.915
36 35 31 0.505 0.0524 0.412 0.619
60 15 12 0.300 0.0558 0.208 0.432
CHILD=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 27 21 0.5933 0.0695 0.4715 0.746
36 7 15 0.2098 0.0642 0.1152 0.382
60 2 4 0.0719 0.0465 0.0203 0.255
CHILD=3
time n.risk n.event survival std.err
12.0000 2.0000 9.0000 0.1818 0.1163
lower 95% CI upper 95% CI
0.0519 0.6369 
Pairwise comparisons using Log-Rank test
data: db and CHILD
1 2
2 0.0000358255 -
3 0.0000000002 0.004
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Encephalopathy..according.to.Child.Pugh.score.=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 115 45 0.740 0.0336 0.677 0.808
36 41 42 0.415 0.0427 0.339 0.508
60 16 17 0.211 0.0418 0.143 0.312
Encephalopathy..according.to.Child.Pugh.score.=2-3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 5 4 0.556 0.166 0.3097 0.997
36 1 4 0.111 0.105 0.0175 0.705
60 1 0 0.111 0.105 0.0175 0.705
Pairwise comparisons using Log-Rank test
data: db and Encephalopathy..according.to.Child.Pugh.score.
1
2-3 0.07
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Ascites..according.to.Child.Pugh.score.=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 106 28 0.806 0.0330 0.744 0.874
36 38 40 0.444 0.0470 0.361 0.546
60 16 14 0.247 0.0476 0.169 0.360
Ascites..according.to.Child.Pugh.score.=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 10 13 0.463 0.1039 0.298 0.719
36 3 4 0.247 0.0975 0.114 0.536
Ascites..according.to.Child.Pugh.score.=3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 4 8 0.333 0.136 0.1498 0.742
36 1 2 0.125 0.108 0.0229 0.682
60 1 0 0.125 0.108 0.0229 0.682
Pairwise comparisons using Log-Rank test
data: db and Ascites..according.to.Child.Pugh.score.
1 2
2 0.000009 -
3 0.005 0.913
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Performance.Status=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 74 18 0.825 0.0377 0.754 0.902
36 26 23 0.515 0.0574 0.414 0.641
60 7 11 0.218 0.0650 0.122 0.391
Performance.Status=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 39 14 0.727 0.0623 0.615 0.860
36 14 19 0.339 0.0678 0.229 0.501
60 10 4 0.242 0.0634 0.145 0.404
Performance.Status=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 10 0.500 0.1118 0.3226 0.775
36 2 5 0.156 0.0957 0.0471 0.519
Performance.Status=3
time n.risk n.event survival std.err
12.0000 1.0000 6.0000 0.2500 0.1531
lower 95% CI upper 95% CI
0.0753 0.8302
Performance.Status=4
time n.risk n.event survival std.err lower 95% CI upper 95% CI
Pairwise comparisons using Log-Rank test
data: db and Performance.Status
0 1 2 3
1 0.53 - - -
2 0.000212 0.01 - -
3 0.000002 0.000448 0.15 -
4 0.000204 0.01 0.46 0.73
P value adjustment method: BH 1 References
- R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.